7 Deer Park Drive
About CytoSorbents, Inc.CytoSorbents Corporation is a leader in critical care immunotherapy, specializing in blood purification. Its flagship product, CytoSorb is CE Mark certified and is currently distributed in 37 countries around the world as a safe and effective extracorporeal cytokine adsorber, designed to reduce the “cytokine storm” or “cytokine release syndrome” that could otherwise cause massive inflammation, organ failure and death in common critical illnesses such as sepsis, burn injury, trauma, lung injury, and pancreatitis, as well as in cancer immunotherapy.
Founders: Christian Steiner and Phillip Chan
CEO: Phillip Chan
Please click here for CytoSorbents job opportunities.
Tweets by CytoSorbents
257 articles with CytoSorbents, Inc.
CytoSorbents Corporation announced that its Chief Executive Officer, Dr.
CytoSorbents Announces the Data Safety Monitoring Board Recommends Continuation of REMOVE Endocarditis Trial
CytoSorbents Corporation announced that the Data Safety Monitoring Board of the German government-funded REMOVE Endocarditis trial recommended continuation of the study following an interim analysis on the first 50 patients of the study.
Agreement brings innovative CytoSorb® therapy to Korea and Mexico and sets the stage for future growth [22-January-2019] MONMOUTH JUNCTION, N.J. , Jan. 22, 2019 /PRNewswire/ -- CytoSorbents Corporation (NASDAQ: CTSO), a critical care immunotherapy leader commercializing its CytoSorb® blood purification technology to treat deadly inflammation in critically-ill and ca
CytoSorbents achieved another year of record growth with total revenue of more than $22.3 million, including product sales of approximately $20.2 million, a 51% increase from a year ago [07-January-2019] MONMOUTH JUNCTION, N.J. , Jan. 7, 2019 /PRNewswire/ -- CytoSorbents Corporation (NASDAQ: CTSO), a critical care immunotherapy leader commercializing its CytoSorb
CytoSorbents Corporation announced that its Chief Executive Officer, Dr. Phillip Chan, MD, PhD, will provide a corporate update and highlight the company's progress at the Biotech Showcase 2019 conference on Monday, January 7, 2019 at 10:30 AM PST in San Francisco, California
CytoSorbents Corporation will present an overview of the company at the 30th Annual Piper Jaffray Healthcare Conference in New York City on November 29, 2018.
CytoSorbents Recognized Again as One of the Fastest Growing Companies in North America on Deloitte's 2018 Technology Fast 500™
Strong international demand for the Company's CytoSorb blood purification technology to control deadly inflammation drives 267% revenue growth over the past three years
CytoSorbents Corporation will report Q3 2018 financial results after the market close on Tuesday, November 6, 2018.
CytoSorbents, Inc. (NASDAQ: CTSO), a critical care immunotherapy leader using its CytoSorb® blood purification technology to treat deadly inflammation in critically-ill and cardiac surgery patients around the world, announced that it will showcase CytoSorb at the 32nd European Association for CardioThoracic Surgery Conference (EACTS) in Milan, Italy from October 18-20, 2018, and the 31st European Society of Intensive Care Medicine Congress (ESICM) in Paris, France from October 20-24, 2018.
Chief Executive Officer, Dr. Phillip Chan, MD, PhD, will present an overview of the company at the Cantor Fitzgerald Global Healthcare Conference today in New York City at the InterContinental New York Barclay Hotel.
Dedicated procedure code for cytokine reduction from the Swiss Federal Statistical Office, a division of the Federal Department of Home Affairs in Switzerland, will become effective January 1, 2019.
World Sepsis Day 2018: CytoSorbents Sponsors the Sepsis Heroes Gala and the Roger Bone Award for Excellence in Sepsis Research
CytoSorbents Corporation commemorates World Sepsis Day 2018 today as a sponsor of the Sepsis Heroes Gala and the Roger Bone Award for Excellence in Sepsis Research.
CytoSorbents Corporation announced that the REFRESH 2-AKI trial protocol amendment that was discussed in the August 2, 2018 earnings press release, has now been approved by the U.S. Food and Drug Administration (FDA).
CytoSorbents to Present at the B. Riley FBR Healthcare Conference and the H.C. Wainwright 20th Annual Global Investment Conference
Conference in New York City on Tuesday, September 4, 2018 at the New York Marriott East Side Hotel
CytoSorbents Awarded up to $3M in SBIR Phase IIB Bridge Funding by NIH/NHLBI to Accelerate U.S. Approval and Commercialization of the HemoDefend™ Blood Transfusion Filter
CytoSorbents Corporation (Nasdaq: CTSO) a critical care immunotherapy leader specializing in blood purification, announced today that the National Heart, Lung, and Blood Institute (NHLBI), a division of the National Institutes of Health (NIH), has awarded the company a three-year Phase IIB Bridge SBIR (Small Business Innovation Research) award
Quarterly CytoSorb Sales Reach $5.2 Million, With Trailing 12-month CytoSorb Sales of $17.4 Million
CytoSorbents Corporation, announced that it has expanded the distribution of CytoSorb® to a total of 53 countries worldwide.
CytoSorbents Corporation will report Q2 2018 financial results after the market close on Thursday, August 2, 2018.
Aferetica and CytoSorbents Debut the PerLife™ System for Organ Preservation and Rehabilitation at the 27th International Congress of the Transplantation Society
PerLife™ Is the First System Integrating a Sorbent Purification Technology to Perfuse, Cleanse, Recondition, and Preserve Harvested Solid Organs for Transplantation
New facility quadruples production capacity and is expected to accelerate margin expansion and drive operating profitability